Navigation Links
London researchers lead innovative new cancer treatment study
Date:12/14/2011

LONDON, ON An innovative treatment technology could give cancer patients new hope for survival. In an international study based at Lawson Health Research Institute and London Health Sciences Centre's London Regional Cancer Program (LRCP), scientists are testing a therapy with the potential to eradicate cancers previously thought to be incurable.

Many complications of cancer occur when it spreads from the original tumour to other areas of the body, such as the brain, liver, or lungs. At this point, the odds of survival are low. Traditional treatments, like chemotherapy, can sometimes slow down the disease, but not stop it.

Using stereotactic ablative radiotherapy, or "SABR," scientists believe they may have found a solution. SABR delivers very large, concentrated doses of radiotherapy to very precise areas, often with few side-effects.

In the newly launched COMET Trial, Dr. David Palma and his colleagues will assess SABR's impact on patient survival, side effects, and quality of life. Over the next four years, 99 patients in Canada and Europe will be randomized to receive either the SABR treatment or the standard-of-care treatment.

"This technology holds promise, in that we are using radiation to target cancers that would previously have been considered incurable," says Dr. Palma. "Although some centres have been using SABR for this purpose with promising results, the COMET study will allow us to see if it really provides a benefit for these patients."

"This trial will help establish the safety and benefit of advanced radiation techniques for the aggressive treatment of patients with a small number of sites of cancer spread," adds Dr. Glenn Bauman, Lawson Scientist and Chair/Chief of the Department of Oncology at LRCP. "Expanding the range of treatment options available and providing better cancer control for these patients are important goals of the trial."

The COMET trial is funded by the Ontario Institute for Cancer Research. In 2012, this Lawson-led study will extend to other collaborators in Ontario, British Columbia, and the Netherlands.

Dr. David Palma is a Scientist at Lawson and a Radiation Oncologist at London Health Sciences Centre's LRCP.


'/>"/>

Contact: Sonya Gilpin
sonya.gilpin@lawsonresearch.com
519-685-8500 x75852
Lawson Health Research Institute
Source:Eurekalert

Related biology news :

1. A London effort to develop point-of-care nanosensors for HIV diagnosis and monitoring
2. Imperial College London and NTU collaborate to offer joint Ph.D. programs in engineering and science
3. Kings College London signs agreement to strengthen Brazilian research links
4. Press registration is now open for EULAR 2011, May 25-28, London
5. Researcher to present discoveries on medical uses of ultrasound to London’s Royal Society
6. Researcher to present discoveries on medical uses of ultrasound to Londons Royal Society
7. Media invitation: Pioneer of organ-on-a-chip technology to speak at Imperial College London
8. NC State researchers get to root of parasite genome
9. Researchers find animal with ability to survive climate change
10. Researchers find an essential gene for forming ears of corn
11. Researchers note differences between people and animals on calorie restriction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
(Date:3/15/2016)... 15, 2016 Yissum Research Development Company ... company of the Hebrew University, announced today the formation ... technology of various human biological indicators. Neteera Technologies has ... from private investors. ... detection of electromagnetic emissions from sweat ducts, enables reliable ...
(Date:3/10/2016)... PUNE, India , March 10, 2016 ... to a new market research report "Identity and Access ... SSO, & Audit, Compliance, and Governance), by Organization Size, ... Forecast to 2020", published by MarketsandMarkets, The market is ... to USD 12.78 Billion by 2020, at a Compound ...
Breaking Biology News(10 mins):
(Date:4/27/2016)... Columbia , April 27, 2016 ... "NanoStruck") (CSE: NSK) (OTCPink: NSKQB) ( Frankfurt ... Anschluss an ihre Pressemitteilung vom 13. August 2015 ... hat, ihre Finanzen um zusätzliche 200.000.000 Einheiten auf ... Kanadische Dollar zu bringen. Davon wurden 157.900.000 Einheiten ...
(Date:4/27/2016)... ... April 27, 2016 , ... PathSensors, Inc., a leading ... Dr. Lamka will assist PathSensors in expanding the use of the company’s CANARY® ... CANARY® test platform for the detection of harmful pathogens, including a number of ...
(Date:4/27/2016)... , April 27, 2016 MedDay, ... disorders, today announces the appointment of Catherine Moukheibir as Chairman ... MedDay,s previous Chairman, Jean Jacques Garaud , who contributed ... change is effective immediately. Catherine started her career ... and London .  She held ...
(Date:4/26/2016)... ... 26, 2016 , ... The European Patent Office (EPO) today announced ... finalists for the European Inventor Award 2016 in the category "Non-European countries." The winners ... a ceremony in Lisbon on June 9th. , The human capacity to walk with ...
Breaking Biology Technology: